CN103086984A - 一类4-苯氨基喹唑啉类衍生物及其制备方法与用途 - Google Patents
一类4-苯氨基喹唑啉类衍生物及其制备方法与用途 Download PDFInfo
- Publication number
- CN103086984A CN103086984A CN2011103424384A CN201110342438A CN103086984A CN 103086984 A CN103086984 A CN 103086984A CN 2011103424384 A CN2011103424384 A CN 2011103424384A CN 201110342438 A CN201110342438 A CN 201110342438A CN 103086984 A CN103086984 A CN 103086984A
- Authority
- CN
- China
- Prior art keywords
- preparation
- compound
- quinazoline
- quinazoline derivative
- acetic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 49
- MTSNDBYBIZSILH-UHFFFAOYSA-N n-phenylquinazolin-4-amine Chemical class N=1C=NC2=CC=CC=C2C=1NC1=CC=CC=C1 MTSNDBYBIZSILH-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- -1 suction filtration Substances 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 229960004756 ethanol Drugs 0.000 claims description 6
- 235000019441 ethanol Nutrition 0.000 claims description 6
- 238000004090 dissolution Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 claims description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000011275 oncology therapy Methods 0.000 claims description 4
- 238000001953 recrystallisation Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000000967 suction filtration Methods 0.000 claims description 4
- MGCGMYPNXAFGFA-UHFFFAOYSA-N 2-amino-5-nitrobenzonitrile Chemical compound NC1=CC=C([N+]([O-])=O)C=C1C#N MGCGMYPNXAFGFA-UHFFFAOYSA-N 0.000 claims description 3
- VPMIAOSOTOODMY-KJAPKAAFSA-N (4r)-6-[(e)-2-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1/C=C/C=1C(C(C)C)=NC(C(C)(C)C)=CC=1C1=CC=C(F)C=C1 VPMIAOSOTOODMY-KJAPKAAFSA-N 0.000 claims description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical class BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims description 2
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 40
- BRKGKBKFUATGIX-UHFFFAOYSA-N 2-(bromomethyl)phenol Chemical compound OC1=CC=CC=C1CBr BRKGKBKFUATGIX-UHFFFAOYSA-N 0.000 description 20
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 20
- 238000005481 NMR spectroscopy Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 11
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 11
- 235000015097 nutrients Nutrition 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- QZOBOLDDGXPTBP-UHFFFAOYSA-N 2-(bromomethyl)thiophene Chemical compound BrCC1=CC=CS1 QZOBOLDDGXPTBP-UHFFFAOYSA-N 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 2
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003246 quinazolines Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- 0 *CNc1cc2c(Nc3cccc(*)c3)ncnc2cc1 Chemical compound *CNc1cc2c(Nc3cccc(*)c3)ncnc2cc1 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- YCOUVYPAOOFTFN-UHFFFAOYSA-N 4-(3-bromophenyl)-1H-quinazoline-4,6-diamine Chemical class BrC=1C=C(C=CC1)C1(NC=NC2=CC=C(C=C12)N)N YCOUVYPAOOFTFN-UHFFFAOYSA-N 0.000 description 1
- HWFVSJRQDJIDSV-UHFFFAOYSA-N 4-[[[4-(3-bromoanilino)quinazolin-6-yl]amino]methyl]phenol Chemical compound C1=CC(O)=CC=C1CNC1=CC=C(N=CN=C2NC=3C=C(Br)C=CC=3)C2=C1 HWFVSJRQDJIDSV-UHFFFAOYSA-N 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- ZJGZDOJZAMDDRS-UHFFFAOYSA-N Brc1ccc(CNc(cc23)ccc2ncnc3Nc2cccc(Br)c2)cc1 Chemical compound Brc1ccc(CNc(cc23)ccc2ncnc3Nc2cccc(Br)c2)cc1 ZJGZDOJZAMDDRS-UHFFFAOYSA-N 0.000 description 1
- RLSZPRPVHOOMBN-KPKJPENVSA-N CN(C)/C=N/c(ccc([N+]([O-])=O)c1)c1C#N Chemical compound CN(C)/C=N/c(ccc([N+]([O-])=O)c1)c1C#N RLSZPRPVHOOMBN-KPKJPENVSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- XFPDPFXODCBZMN-UHFFFAOYSA-N S(=O)(=O)(O)C1=CC=C(C)C=C1.S(=O)(=O)(O)C1=CC=C(C)C=C1.N(C1=CC=CC=C1)C1=NC=NC2=CC=CC=C12 Chemical compound S(=O)(=O)(O)C1=CC=C(C)C=C1.S(=O)(=O)(O)C1=CC=C(C)C=C1.N(C1=CC=CC=C1)C1=NC=NC2=CC=CC=C12 XFPDPFXODCBZMN-UHFFFAOYSA-N 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 229960001320 lapatinib ditosylate Drugs 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- AZBFJBJXUQUQLF-UHFFFAOYSA-N n-(1,5-dimethylpyrrolidin-3-yl)pyrrolidine-1-carboxamide Chemical compound C1N(C)C(C)CC1NC(=O)N1CCCC1 AZBFJBJXUQUQLF-UHFFFAOYSA-N 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- CZAAKPFIWJXPQT-UHFFFAOYSA-N quinazolin-2-amine Chemical class C1=CC=CC2=NC(N)=NC=C21 CZAAKPFIWJXPQT-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- RNWDENXDCQXZLH-UHFFFAOYSA-N quinazoline-4,6-diamine Chemical class N1=CN=C(N)C2=CC(N)=CC=C21 RNWDENXDCQXZLH-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Abstract
Description
技术领域
本发明涉及一类4-苯氨基喹唑啉类衍生物及其制备方法与作为抗癌药物的用途。
背景技术。
蛋白酪氨酸激酶(PTK)是一类具有酪氨酸激酶活性的蛋白质,可分为受体型和非受体型两种,它们能催化ATP上的磷酸基团转移到许多重要蛋白质的酪氨酸残基上,使其发生磷酸化。蛋白酪氨酸激酶在细胞内的信号转导通路中占据了十分重要的地位,调节着细胞体内生长、分化、死亡等一系列生理过程。蛋白酪氨酸激酶功能的失调则会引发生物体内的一系列疾病。已有的资料表明,超过50%的原癌基因和癌基因产物都具有蛋白酪氨酸激酶活性,酪氨酸蛋白激酶过度表达时,会阻碍细胞程序死亡,使细胞的生长调控失控,始终处于增生状态,发展成为恶性肿瘤。因此,以酪氨酸激酶为靶点进行药物研发成为国际上抗肿瘤药物研究的热点。
表皮生长因子受体(EGFR)广泛分布于哺乳动物的上皮细胞膜上,与细胞的增殖、死亡和分化有关,是细胞外生长信号传递到细胞内的枢纽。EGFR家族由4个成员组成,包括:EGFR(HER1/ErbB-1),ErbB-2(HER2/neu),ErbB-3(HER3)和ErbB-4(HER4)。EGFR酪氨酸激酶介导的细胞生长信号通路在癌症的形成和发展过程中起着重要作用,许多类型的实体肿瘤,如非小细胞肺癌(NSCLC)、乳腺癌、卵巢癌、头颈癌、胃癌、***癌、膀胱癌、结肠癌和胶质细胞瘤等均出现一种或几种EGFR家族受体的过度表达。
喹唑啉类化合物最主要的应用就是可以作为EGFR酪氨酸激酶抑制剂,从而表现出较好的抗癌活性。尤其是4-氨基取代的喹唑啉类化合物对EGFR(表皮生长因子受体)酪氨酸激酶具有抑制作用,从而表现出抗肺癌、胃癌、***癌等活性,引起人们的广泛关注。PD153035是第一个被报道的选择性EGFR酪氨酸激酶小分子抑制剂,它属于4-苯氨基喹唑啉类化合物。PD153035由于理化性质的原因,难以成为药物,但可用于指导发现更新的、更有临床价值的此类化合物。随后,以其为先导设计合成的针对EGFR的药物吉非替尼、埃罗替尼、拉帕替尼相继上市。喹唑啉是一类用途广泛,具有较高生物活性的重要杂环化合物,从而其成为生物学和化学界研究的热点。因此,本发明以4-氨基喹唑啉为先导化合物,进行结构修饰,筛选高活性抗癌药物,很有意义。
发明内容
本发明的目的在于提供一类4-苯氨基喹唑啉类衍生物以及它们的制备方法与用途。
本发明的技术方案如下:
一类4-苯氨基喹唑啉类衍生物,其特征是它有如下通式:
式中X为Cl、Br;
R为
一种制备上述的4-苯氨基喹唑啉类衍生物的方法,其特征是它由下列步骤组成:
步骤1.将0.1mol 2-氰基-4-硝基苯胺缓慢加入50mlN,N-二甲基甲酰胺二甲基缩醛,在70-75℃下反应2h。反应结束后冷却至室温,析出红色固体,抽滤,***洗涤。
步骤2.将0.1mol卤代苯胺加入50ml乙酸,然后缓慢加入步骤1所得产物,在70-75℃下反应1-2h,析出大量黄色固体,抽滤,先用乙酸洗涤,然后再用***洗涤,烘干。
步骤3.取步骤2所得化合物2g,与140ml无水乙醇,40ml水,6ml醋酸,3g铁粉加入于500ml的烧瓶中,然后加热60-80℃回流搅拌反应5-6小时,反应结束后,将反应液全部倒入500ml烧杯中,然后冷却至室温,加入40ml浓氨水搅拌。减压蒸馏除去乙醇,用乙酸乙酯萃取。萃取液拌入适量硅胶,旋干,干法上柱,乙酸乙酯∶石油醚=4∶1,柱层析,得深黄色产物。
步骤4.取步骤3所得黄色化合物1mmol,溶于5ml乙腈,加入1mmol取代苄基溴,2mmolNaOH,90℃回流,反应4-5h,减压蒸干乙腈,乙酸乙酯溶解,水洗除去NaOH,无水硫酸钠干燥,减压蒸干乙酸乙酯,乙醇重结晶,得目标化合物。
实验结果表明,本发明的新型4-苯氨基喹唑啉类衍生物对各种癌细胞具有明显的抑制作用。因此本发明的4-苯氨喹唑啉类和取代肉桂酸的复合物可以应用于制备抗癌药物。
具体实施方式
通过以下实施例进一步详细说明本发明,但本发明的范围并不受这些实施例的任何限制。
实施例一:2-((4-((3-溴苯基)氨基)喹唑啉6-基)氨基)甲基)苯酚(化合物1)的制备
取N4-(3-溴苯基)喹唑啉-4,6-二胺1mmol,溶于5ml乙腈,加入1mmol 2-羟基苄基溴,2mmolNaOH,90℃回流,反应4-5h,减压蒸干乙腈,乙酸乙酯溶解,水洗除去NaOH,无水硫酸钠干燥,减压蒸干乙酸乙酯,乙醇重结晶,得目标化合物。白色粉末,产率80%,Mp 235-236℃;1H NMR(300MHz,DMSO-d6,δppm):4.38(d,J=5.49Hz,2H,CH2),6.40(t,J=5.58Hz,1H),6.76(t,J=6.96Hz,1H),6.86(d,J=8.07Hz,1H),7.04-7.11(m,1H),7.24-7.40(m,5H),7.55(d,J=8.94Hz,1H),7.89(d,J=8.04Hz,1H),8.16(s,1H,NH),8.39(s,1H),9.44(s,1H,NHCH2),9.60(s,1H,OH).ESI-MS:421.1(C21H17BrN4O,[M+H]+).Anal.Calcdfor C21H17BrN4O:C,59.87%;H,4.07%;N,13.30%.Found:C,59.53%;H,4.36%;N,13.57%.
实施例二:4-(((4-((3-溴苯基)氨基)喹唑啉6-基)氨基)甲基)苯酚(化合物2)的制备
制备方法同实施例一。以4-羟基苄基溴代替2-羟基苄基溴,得目标化合物。白色固体,产率82%。Mp 239-240℃;1H NMR(300MHz,DMSO-d6,δppm):4.30(d,J=5.31Hz,2H,CH2),6.56(s,1H),6.74(t,J=8.4Hz,1H),7.24-7.37(m,6H),7.54(d,J=8.97Hz,1H),7.91(d,J=8.22Hz,1H),8.18(s,1H,NH),8.38(s,1H),9.30(s,1H,OH),9.43(s,1H,NHCH2).ESI-MS:421.1(C21H17BrN4O,[M+H]+).AnalCalcd for C21H17BrN4O:C,59.87%;H,4.07%;N,13.30%.Found:C,59.72%;H,4.45%;N,13.11%.
实施例三:N4-(3-溴苯基)-N6-(2-甲氧基)喹唑啉-4,6-二胺(化合物3)的制备
制备方法同实施例一。以2-甲氧基苄基溴代替2-羟基苄基溴,得目标化合物。白色固体,产率81%。Mp 105-107℃;1H NMR(300MHz,DMSO-d6,δppm):3.85(s,3H,OCH3),4.41(d,J=5.67Hz,2H,CH2),6.47(s,1H),6.92(t,J=7.40Hz,1H),7.04(d,J=8.04Hz,1H),7.24-7.39(m,6H),7.56(d,J=8.94Hz,1H),7.84(d,J=8.04Hz,1H),8.15(s,1H,NH),8.38(s,1H),9.42(s,1H,NHCH2).ESI-MS:435.1(C22H19BrN4O,[M+H]+).Anal.Calcd for C22H19BrN4O:C,60.70%;H,4.40%;N,12.87%.Found:C,60.21%;H,4.36%;N,13.07%.
实施例四:N4-(3-溴苯基)-N6-(4-氟苄基)喹唑啉-4,6-二胺(化合物4)的制备
制备方法同实施例一。以4-氟苄基溴代替2-羟基苄基溴,得目标化合物。白色固体,产率78%。Mp 122-124℃;1H NMR(300MHz,DMSO-d6,δppm):4.44(d,J=5.85Hz,2H,CH2),6.73(t,J=5.58Hz,1H),7.18(t,J=8.88Hz,2H),7.26(d,J=8.58Hz,1H),7.34(t,J=7.95Hz,3H),7.47-7.52(m,2H),7.56(d,J=8.94Hz,1H),7.89(d,J=8.07Hz,1H),8.17(s,1H,NH),8.39(s,1H),9.37(s,1H,NHCH2).ESI-MS:423.1(C21H16BrFN4,[M+H]+).Anal.Calcd for C21H17BrN4O:C,59.59%;H,3.81%;N,13.24%.Found:C,59.83%;H,4.26%;N,12.87%.
实施例五:N4-(3-溴苯基)-N6-(4-氯苄基)喹唑啉-4,6-二胺(化合物5)的制备
制备方法同实施例一。以4-氯苄基溴代替2-羟基苄基溴,得目标化合物。白色固体,产率79%。Mp 119-121℃;1H NMR(300MHz,DMSO-d6,δppm):4.46(d,J=5.85Hz,2H,CH2),6.78(t,J=5.85Hz,1H),7.25-7.37(m,4H),7.41(d,J=8.58Hz,2H),7.48(d,J=8.61Hz,2H),7.57(d,J=8.79Hz,1H),7.88(d,J=8.04Hz,1H),8.16(s,1H,NH),8.39(s,1H),9.36(s,1H,NHCH2).ESI-MS:439.0(C21H16BrClN4,[M+H]+).Anal.Calcd for C21H16BrClN4:C,57.36%;H,3.67%;N,12.74%.Found:C,59.83%;H,4.06%;N,12.57%.
实施例六:N4-(3-溴苯基)-N6-(4-溴苄基)喹唑啉-4,6-二胺(化合物6)的制备
制备方法同实施例一。以4-溴苄基溴代替2-羟基苄基溴,得目标化合物。白色固体,产率83%。Mp 125-127℃;1H NMR(300MHz,DMSO-d6,δppm):4.44(d,J=6.03Hz,2H,CH2),6.78(t,J=5.94Hz,1H),7.24-7.36(m,4H),7.41(d,J=8.4Hz,2H),7.53-7.58(m,3H),7.88(d,J=8.07Hz,1H),8.16(s,1H,NH),8.39(s,1H),9.35(s,1H,NHCH2).ESI-MS:482.9(C21H16Br2N4,[M+H]+).Anal.Calcd forC21H16Br2N4:C,52.09;H,3.33%;N,11.57%.Found:C,52.34%;H,3.36%;N,11.27%.
实施例七:N4-(3-溴苯基)-N6-(2-氯苄基)喹唑啉-4,6-二胺(化合物7)的制备
制备方法同实施例一。以2-氯苄基溴代替2-羟基苄基溴,得目标化合物。白色固体,产率82%。Mp 199-200℃;1H NMR(300MHz,DMSO-d6,δppm):4.53(d,J=5.67Hz,2H,CH2),6.69(t,J=5.76Hz,1H),6.76(t,J=6.96Hz,1H),7.24-7.40(m,6H),7.48-7.53(m,2H),7.59(d,J=7.71Hz,1H),7.87(d,J=8.22Hz,1H),8.16(s,1H,NH),8.40(s,1H),9.41(s,1H,NHCH2).ESI-MS:439.0(C21H16BrClN4,[M+H]+).Anal.Calcd for C21H16BrClN4:C,57.36%;H,3.67%;N,12.74%.Found:C,56.97%;H,3.36%;N,13.09%.
实施例八:N4-(3-溴苯基)-N6-(2-溴苄基)喹唑啉-4,6-二胺(化合物8)的制备
制备方法同实施例一。以2-溴苄基溴代替2-羟基苄基溴,得目标化合物。白色固体,产率80%。Mp 213-214℃;1H NMR(300MHz,DMSO-d6,δppm):4.49(d,J=5.49Hz,2H,CH2),6.68(t,J=5.76Hz,1H),7.23-7.40(m,6H),7.50(d,J=6.95Hz,1H),7.59(d,J=8.97Hz,1H),7.67(dd,J1=7.86Hz,J2=8.04Hz,1H),7.87(d,J=8.04Hz,1H),8.16(s,1H,NH),8.39(s,1H),9.44(s,1H,NHCH2).ESI-MS:482.9(C21H16Br2N4,[M+H]+).Anal.Calcd for C21H16Br2N4:C,52.09%;H,3.33%;N,11.57%.Found:C,51.89%;H,3.46%;N,11.76%.
实施例九:N4-(3-溴苯基)-N6-((噻吩-2-基)甲基)喹唑啉-4,6-二胺(化合物9)的制备
制备方法同实施例一。以2-溴甲基噻吩代替2-羟基苄基溴,得目标化合物。白色固体,产率85%。Mp 222-224℃;1H NMR(300MHz,DMSO-d6,δppm):4.65(d,J=5.85Hz,2H,CH2),6.78(t,J=5.85Hz,1H),6.76(t,J=6.96Hz,1H),6.86(d,J=8.07Hz,1H),6.98-7.01(m,1H),7.18(d,J=3.45Hz,1H),7.25-7.42(m,5H),7.57(d,J=8.94Hz,1H),7.90(d,J=8.04Hz,1H),8.18(s,1H,NH),8.40(s,1H),9.39(s,1H,NHCH2).ESI-MS:411.1(C19H15BrN4S,[M+H]+).Anal.Calcd forC19H15BrN4S:C,55.48%;H,3.68%;N,13.62%.Found:C,55.53%;H,4.01%;N,13.53%.
实施例十:N4-(3-溴苯基)-N6-(4-甲氧基)喹唑啉-4,6-二胺(化合物10)的制备
制备方法同实施例一。以4-甲氧基苄基溴代替2-羟基苄基溴,得目标化合物。白色固体,产率83%。Mp 115-117℃;1H NMR(300MHz,DMSO-d6,δppm):3.37(s,3H,OCH3),4.37(d,J=5.49Hz,2H,CH2),6.64(t,J=5.58Hz,1H),6.93(d,J=8.61Hz,2H),7.25-7.40(m,6H),7.56(d,J=8.97Hz,1H),7.91(d,J=8.04Hz,1H),8.18(s,1H,NH),8.39(s,1H),9.39(s,1H,NHCH2).ESI-MS:435.1(C22H19BrN4O,[M+H]+).Anal.Calcd for C22H19BrN4O:C,60.70%;H,4.40%;N,12.87%.Found:C,60.43%;H,4.34%;N,13.07%.
实施例十一:2-((4-((3-氯苯基)氨基)喹唑啉6-基)氨基)甲基)苯酚(化合物11)的制备
取N4-(3-氯苯基)喹唑啉-4,6-二胺1mmol,溶于5ml乙腈,加入1mmol 2-羟基苄基溴,2mmolNaOH,90℃回流,反应4-5h,减压蒸干乙腈,乙酸乙酯溶解,水洗除去NaOH,无水硫酸钠干燥,减压蒸干乙酸乙酯,乙醇重结晶,得目标化合物。白色粉末,产率80%,Mp 232-234℃;1H NMR(300MHz,DMSO-d6,δppm):4.38(d,J=5.49Hz,2H,CH2),6.41(t,J=5.4Hz,1H),6.77(t,J=7.41Hz,1H),6.86(d,J=8.04Hz,1H),7.07-7.14(m,2H),7.30(t,J=6.95Hz,2H),7.40(t,J=8.15Hz,2H),7.55(d,J=8.97Hz,1H),7.83(d,J=8.22Hz,1H),8.06(s,1H,NH),8.40(s,1H),9.45(s,1H,NHCH2),9.61(s,1H,OH).ESI-MS:377.1(C21H17ClN4O,[M+H]+).Anal.Calcd for C21H17ClN4O:C,66.93%;H,4.55%;N,14.87%.Found:C,67.03%;H,4.36%;N,14.59%.
实施例十二:4-(((4-((3-氯苯基)氨基)喹唑啉6-基)氨基)甲基)苯酚(化合物12)的制备
制备方法同实施例十一。以4-羟基苄基溴代替2-羟基苄基溴,得目标化合物。白色固体,产率81%。Mp 228-230℃;1H NMR(300MHz,DMSO-d6,δppm):4.31(d,J=5.49Hz,2H,CH2),6.56(s,1H),6.75(d,J=8.61Hz,2H),7.13(dd,J1=7.86Hz,J2=7.86Hz,1H),7.25-7.43(m,5H),7.30(t,J=6.95Hz,2H),7.40(t,J=8.15Hz,2H),7.55(d,J=8.97Hz,1H),7.84(d,J=8.22Hz,1H),8.07(s,1H,NH),8.39(s,1H),9.32(s,1H,OH),9.40(s,1H,NHCH2).ESI-MS:377.1(C21H17ClN4O,[M+H]+).Anal.Calcd for C21H17ClN4O:C,66.93%;H,4.55%;N,14.87%.Found:C,67.14%;H,4.63%;N,14.49%.
实施例十三:N4-(3-氯苯基)-N6-(2-甲氧基)喹唑啉-4,6-二胺(化合物13)的制备
制备方法同实施例十一。以2-甲氧基苄基溴代替2-羟基苄基溴,得目标化合物。白色固体,产率85%。Mp 99-101℃;1H NMR(500MHz,DMSO-d6,δppm):3.86(s,3H,OCH3),4.43(d,J=6Hz,2H,CH2),6.50(t,J=5.75Hz,1H),6.93(t,J=7.5Hz,1H),7.04(d,J=8.5Hz,1H),7.13(dd,J1=8Hz,J2=8Hz,1H),7.26-7.31(m,2H),7.35-7.42(m,3H),7.57(d,J=8.5Hz,1H),7.83(d,J=8.5Hz,1H),8.05(s,1H,NH),8.40(s,1H),9.44(s,1H,NHCH2).ESI-MS:391.1(C22H19ClN4O,[M+H]+).Anal.Calcd for C22H19ClN4O:C,67.60%;H,4.90%;N,14.33%.Found:C,67.26%;H,5.24%;N,14.65%.
实施例十四:N4-(3-氯苯基)-N6-(4-氟苄基)喹唑啉-4,6-二胺(化合物14)的制备
制备方法同实施例十一。以4-氟苄基溴代替2-羟基苄基溴,得目标化合物。白色固体,产率82%。Mp 115-117℃;1H NMR(300MHz,DMSO-d6,δppm):4.44(d,J=5.67Hz,2H,CH2),6.74(t,J=5.85Hz,1H),7.12-7.21(m,3H),7.33-7.43(m,3H),7.47-7.58(m,3H),7.82(d,J=8.22Hz,1H),8.06(s,1H,NH),8.40(s,1H),9.39(s,1H,NHCH2).ESI-MS:379.1(C21H16ClFN4,[M+H]+).Anal.Calcd forC21H16ClFN4:C,66.58%;H,4.26%;N,14.79%.Found:C,66.83%;H,4.62%;N,14.41%.
实施例十五:N4-(3-氯苯基)-N6-(4-氯苄基)喹唑啉-4,6-二胺(化合物15)的制备
制备方法同实施例十一。以4-氯苄基溴代替2-羟基苄基溴,得目标化合物。白色固体,产率86%。Mp 121-123℃;1H NMR(300MHz,DMSO-d6,δppm):4.46(d,J=5.85Hz,2H,CH2),6.79(s,1H),7.13(d,J=9.15Hz,1H),7.31-7.49(m,6H),7.57(d,J=8.94Hz,1H),7.81(d,J=9.15Hz,1H),8.05(s,1H,NH),8.39(s,1H),9.38(s,1H,NHCH2).ESI-MS:395.0(C21H16Cl2N4,[M+H]+).Anal.Calcd forC21H16Cl2N4:C,63.81%;H,4.08%;N,14.17%.Found:C,64.03%;H,4.21%;N,13.84%.
实施例十六:N4-(3-氯苯基)-N6-(4-溴苄基)喹唑啉-4,6-二胺(化合物16)的制备
制备方法同实施例十一。以4-溴苄基溴代替2-羟基苄基溴,得目标化合物。白色固体,产率78%。Mp 126-128℃;1H NMR(500MHz,DMSO-d6,δppm):4.41(d,J=6Hz,2H,CH2),6.76(t,J=5.75Hz,1H),7.07(dd,J1=7.5Hz,J2=8Hz,1H),7.29-7.38(m,6H),7.49(d,J=8.2Hz,2H),7.56(d,J=9Hz,1H),7.79(d,J=8Hz,1H),8.04(s,1H,NH),8.39(s,1H),9.38(s,1H,NHCH2).ESI-MS:439.0(C21H16BrClN4,[M+H]+).Anal.Calcd for C21H16BrClN4:C,57.36;H,3.67%;N,12.74%.Found:C,57.24%;H,3.39%;N,13.05%.
实施例十七:N4-(3-氯苯基)-N6-(2-氯苄基)喹唑啉-4,6-二胺(化合物17)的制备
制备方法同实施例十一。以2-氯苄基溴代替2-羟基苄基溴,得目标化合物。白色固体,产率76%。Mp 195-197℃;1H NMR(500MHz,DMSO-d6,δppm):4.54(d,J=5.5Hz,2H),6.70(t,J=5.5Hz,2H),7.12(dd,J1=6.5Hz,J2=6.5Hz,1H),7.31-7.33(m,3H),7.37-7.40(m,2H),7.48-7.52(m,2H),7.60(d,J=9Hz,1H),7.81(d,J=8Hz,1H),8.05(s,1H,NH),8.41(s,1H),9.43(s,1H,NHCH2).ESI-MS:394.1(C21H16Cl2N4,[M+H]+).Anal.Calcd for C21H16Cl2N4:C,63.81%;H,4.08%;N,14.17%.Found:C,64.07%;H,3.95%;N,14.09%.
实施例十八:N4-(3-氯苯基)-N6-(2-溴苄基)喹唑啉-4,6-二胺(化合物18)的制备
制备方法同实施例十一。以2-氯苄基溴代替2-羟基苄基溴,得目标化合物。白色固体,产率82%。Mp 203-205℃;1H NMR(300MHz,DMSO-d6,δppm):4.50(d,J=5.67Hz,2H,CH2),6.70(s,1H),7.14(d,J=7.68Hz,1H),7.25(t,J=6.95Hz,1H),7.33-7.43(m,4H),7.59(d,J=8.97Hz,1H),7.50(dd,J1=7.86Hz,J2=7.5Hz,1H),7.59(d,J=9.15Hz,1H),7.67(d,J=7.86Hz,1H),7.80(d,J=8.97Hz,1H),8.04(s,1H,NH),8.41(s,1H),9.46(s,1H,NHCH2).ESI-MS:439.0(C21H16BrClN4,[M+H]+).Anal.Calcd for C21H16BrClN4:C,57.36%;H,3.67%;N,12.74%.Found:C,56.99%;H,3.42%;N,13.06%.
实施例十九:N4-(3-氯苯基)-N6-((噻吩-2-基)甲基)喹唑啉-4,6-二胺(化合物19)
制备方法同实施例十一。以2-溴甲基噻吩代替2-羟基苄基溴,得目标化合物。白色固体,产率81%。Mp 218-220℃;1H NMR(300MHz,DMSO-d6,δppm):4.66(d,J=5.85Hz,2H,CH2),6.78(t,J=5.76Hz,1H),7.00(t,J=4.22Hz,1H),7.13-7.19(m,2H),7.35-7.44(m,4H),7.57(d,J=8.76Hz,1H),7.84(d,J=8.94Hz,1H),8.07(s,1H,NH),8.41(s,1H),9.40(s,1H,NHCH2).ESI-MS:366.1(C19H15ClN4S,[M+H]+).Anal.Calcd for C19H15ClN4S:C,62.20%;H,4.12%;N,15.27%.Found:C,61.99%;H,4.03%;N,15.53%.
实施例二十:N4-(3-氯苯基)-N6-(4-甲氧基)喹唑啉-4,6-二胺(化合物20)的制备
制备方法同实施例十一。以4-甲氧基苄基溴代替2-羟基苄基溴,得目标化合物。白色固体,产率83%。Mp 103-104℃;1H NMR(300MHz,DMSO-d6,δppm):3.73(s,3H,OCH3),4.38(d,J=5.49Hz,2H,CH2),6.64(t,J=5.48Hz,1H),6.93(d,J=8.61Hz,2H),7.13(dd,J1=8.07Hz,J2=7.86Hz,1H),7.33-7.43(m,5H),7.56(d,J=8.97Hz,1H),7.85(d,J=8.25Hz,1H),8.07(s,1H,NH),8.40(s,1H),9.40(s,1H,NHCH2).ESI-MS:391.1(C22H19ClN4O,[M+H]+).Anal.Calcd for C22H19ClN4O:C,67.60%;H,4.90%;N,14.33%.Found:C,67.13%;H,5.12%;N,14.36%.
实施例二十一:一类4-苯氨基喹唑啉类衍生物抗癌活性研究
采用MTT[3-(4,5)-双甲基-2-噻唑-(2,5)-苯基溴化四氮唑蓝]法来测定4-苯氨基喹唑啉类衍生物对人体肺癌乳腺癌细胞株(MCF7)的抑制率,计算IC50值(μM)。
(1)培养液(每升)的配制:①悬浮细胞:RPMI-1640培养粉一袋(10.4g),新生牛血清100ml,青霉素溶液(20万U/ml)0.5ml,链霉素溶液(20万U/ml)0.5ml,加三蒸水溶解后,用5.6%的NaHCO3溶液调PH值至7.2-7.4,最后定容至1000ml。过滤灭菌。②贴壁细胞:同上,再加入NaHCO32.00g,HEPES 2.38g。
(2)D-Hanks缓冲液(每升)的配制:NaCl 8.00g,KCl 0.40g,Na2HPO4·12H2O 0.06g,KH2PO4 0.06g,NaHCO3 0.35g。高压灭菌。
(3)胰蛋白酶液的配制:利用D-Hanks缓冲液配成浓度为0.5%胰蛋白酶液。过滤除菌。
(4)实验药液的配制:将测试样品用少量的三蒸水溶解配成储备液,一般按实验最高浓度的10倍配制储备液。根据化合物溶解性不同,可用三蒸水直接溶解,或用少量DMSO助溶,再加三蒸水溶解。DMSO在培养液中的浓度不宜过大,加药后的每孔细胞悬液中DMSO的终浓度一般不超过0.05%-0.1%。储备液保存于-20℃冰箱中备用。
(5)人乳腺癌细胞MCF7的培养:为悬浮生长细胞,常规培养于RPMI-1640培养液内(含10%小牛血清、100U/ml链霉素),置于37℃、5%CO2培养箱中培养,每隔3-4天传代一次。传代时将原瓶中培养液转移至离心管中,1000rpm离心5min,弃去原培养液,加入等量新鲜培养液,吹打均匀,移取适量至新鲜培养瓶中,再补充新鲜培养液至原体积(培养液体积约为培养瓶容量的1/10)。
(6)细胞孵育:取对数生长期的乳腺癌肿瘤细胞,调细胞悬液浓度为1-1.5×105个ml-1。在96孔培养板中每孔加细胞悬液100μl,置37℃,5%CO2培养箱中培养24h。培养24h后,分别按设计加入药液。
(8)加药:将测试药液按照最终浓度的浓度梯度分别加入到各个孔中,每个浓度设6个平行孔。实验分为药物试验组(分别加入不同浓度的测试药)、对照组(只加培养液和细胞,不加测试药)和空白组(只加培养液,不加细胞和测试药)。将加药后的96孔板置于37℃,5%CO2培养箱中培养48h。阳性对照药物的活性按照测试样品的方法测定。
(9)存活细胞的测定:在培养了48h后的96孔板中,每孔加MTT 40μl(用D-Hanks缓冲液配成4mg/ml)。在37℃放置4h后,移去上清液。每孔加150μl DMSO,振荡5min,使formazan结晶溶解。最后,利用自动酶标仪在570nm波长处检测各孔的光密度(OD值)。
抑制率的计算:细胞生长的抑制率按照下列公式计算:
生长抑制率=(1-存活率)×100%=[1-(OD实验-OD空白)/(OD对照-OD空 白)]×100%(OD实验表示测试药物组的平均光密度,OD对照表示对照组的平均光密度,OD空白表示对照组的平均光密度)。
半数抑制浓度(IC50)定义为当50%的肿瘤细胞存活时的药物浓度。根据测定的光密度(OD值),制作细胞生长抑制率的标准曲线,在标准曲线上求得其对应的药物浓度。
测得的IC50见表1所示
表1本发明所列4-苯氨基喹唑啉类衍生物对肿瘤细胞的抑制IC50值(μM)
测得的IC50见表1所示
Claims (3)
2.一种制备权利要求1所述的4-苯氨基喹唑啉类衍生物的方法,其特征是它由下列步骤组成:
步骤1.将0.1mol 2-氰基-4-硝基苯胺缓慢加入50mlN,N-二甲基甲酰胺二甲基缩醛,在70-75℃下反应2h。反应结束后冷却至室温,析出红色固体,抽滤,***洗涤。
步骤2.将0.1mol卤代苯胺加入50ml乙酸,然后缓慢加入步骤1所得产物,在70-75℃下反应1-2h,析出大量黄色固体,抽滤,先用乙酸洗涤,然后再用***洗涤,烘干。
步骤3.取步骤2所得化合物2g,与140ml无水乙醇,40ml水,6ml醋酸,3g铁粉加入于500ml的烧瓶中,然后加热60-80℃回流搅拌反应5-6小时,反应结束后,将反应液全部倒入500ml烧杯中,然后冷却至室温,加入40ml浓氨水搅拌。减压蒸馏除去乙醇,用乙酸乙酯萃取。萃取液拌入适量硅胶,旋干,干法上柱,乙酸乙酯∶石油醚=4∶1,柱层析,得深黄色产物。
步骤4.取步骤3所得黄色化合物1mmol,溶于5ml乙腈,加入1mmol取代苄基溴,2mmolNaOH,90℃回流,反应4-5h,减压蒸干乙腈,乙酸乙酯溶解,水洗除去NaOH,无水硫酸钠干燥,减压蒸干乙酸乙酯,乙醇重结晶,得目标化合物。
3.权利要求1所述的4-苯氨基喹唑啉类衍生物在制备抗癌药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011103424384A CN103086984A (zh) | 2011-11-03 | 2011-11-03 | 一类4-苯氨基喹唑啉类衍生物及其制备方法与用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011103424384A CN103086984A (zh) | 2011-11-03 | 2011-11-03 | 一类4-苯氨基喹唑啉类衍生物及其制备方法与用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103086984A true CN103086984A (zh) | 2013-05-08 |
Family
ID=48200168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011103424384A Pending CN103086984A (zh) | 2011-11-03 | 2011-11-03 | 一类4-苯氨基喹唑啉类衍生物及其制备方法与用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103086984A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1211240A (zh) * | 1996-02-14 | 1999-03-17 | 曾尼卡有限公司 | 作为抗肿瘤剂的喹唑啉衍生物 |
CN1956966A (zh) * | 2004-02-19 | 2007-05-02 | 雷克斯安公司 | 喹唑啉衍生物及其治疗用途 |
-
2011
- 2011-11-03 CN CN2011103424384A patent/CN103086984A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1211240A (zh) * | 1996-02-14 | 1999-03-17 | 曾尼卡有限公司 | 作为抗肿瘤剂的喹唑啉衍生物 |
CN1956966A (zh) * | 2004-02-19 | 2007-05-02 | 雷克斯安公司 | 喹唑啉衍生物及其治疗用途 |
Non-Patent Citations (1)
Title |
---|
DONG-DONG LI ET AL: "The combination of 4-anilinoquinazoline and cinnamic acid: A novel mode of binding to the epidermal growth factor receptor tyrosine kinase", 《BIOORGANIC & MEDICINAL CHEMISTRY》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105175410A (zh) | 三嗪类化合物及其制备方法和抗肿瘤应用 | |
CN101723890B (zh) | 芳基硫脲及其制备方法和用途 | |
CN102617391B (zh) | 一种白藜芦醇苯丙烯酰胺类衍生物、其制备方法及其用途 | |
CN104447496B (zh) | 异吲哚‑1,3‑二酮类化合物及其制备方法与应用 | |
CN106946868B (zh) | 一氧化氮供体型香豆素衍生物、其制备方法及医药用途 | |
CN112300082B (zh) | 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途 | |
JP5504460B2 (ja) | 4−フェニルアミノキナゾリン誘導体の塩形態 | |
CN103483324A (zh) | 拉帕替尼的新制备方法 | |
CN103058938A (zh) | 4-苯胺喹唑啉类和取代肉桂酸的复合物及其制备方法与用途 | |
CN102060848B (zh) | 芳香胺取代的嘧啶衍生物的制备及用途 | |
CN103936631A (zh) | 一种含有肟基的联苯脲化合物及其制备方法和应用 | |
CN106045980A (zh) | 一种喹唑啉衍生物及其制备方法 | |
CN103086984A (zh) | 一类4-苯氨基喹唑啉类衍生物及其制备方法与用途 | |
CN105061441A (zh) | 含哌嗪等氮杂环的香豆素并吡唑类化合物及其制备与在抑制肿瘤细胞中的应用 | |
CN102675205B (zh) | 一种吡唑肟醚类化合物及其制备与在抗癌治疗中的应用 | |
CN106083740B (zh) | 一种含1,2,3-三氮唑的4-苯胺基喹唑啉衍生物及制备方法 | |
CN104119319B (zh) | 含1,2,3-三氮唑和脲结构单元的嘧啶衍生物及其制备方法和用途 | |
CN105461723A (zh) | 酞嗪并[1,2,b]喹唑啉-8-酮化合物及其制备方法和在抗肿瘤药物中的应用 | |
CN101723894B (zh) | N-喹啉酰胺类衍生物及其制法与用途 | |
CN103709146B (zh) | 一类含苯并咪唑结构的喹啉-4-胺衍生物、其制法及医药用途 | |
CN105037265A (zh) | 一类含查尔酮骨架的喹啉酮衍生物的制备方法及在抗癌药物中的应用 | |
CN111518078B (zh) | 一种含氨基吡啶的嘧啶类化合物及其应用 | |
CN105061440A (zh) | 含乙酰氨基氮杂环的香豆素并吡唑类化合物及其制备与在抑制肿瘤细胞中的应用 | |
CN104725364B (zh) | 6,7‑二甲氧基‑喹唑啉‑4‑胺衍生物、其制备方法及医药用途 | |
CN103373966A (zh) | 一类4-苯胺喹唑啉类酰胺衍生物及其制备方法与用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130508 |